Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Shares Shorted: Short Interest Down 91.4% in October

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 16,869 shares, a decline of 91.4% from the October 15th total of 195,736 shares. Currently, 2.1% of the company’s stock are short sold. Based on an average daily volume of 77,912 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Hong Kong Pharma Digital Technology in a report on Wednesday. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, Hong Kong Pharma Digital Technology presently has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Stock Down 1.6%

Shares of HKPD opened at $1.50 on Friday. Hong Kong Pharma Digital Technology has a 1-year low of $1.34 and a 1-year high of $29.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.86 and a quick ratio of 3.75. The firm has a fifty day moving average price of $2.15 and a 200 day moving average price of $8.73.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.